By Analou De Vera The Food and Drug Administration (FDA) has warned the public against the presence of six unregistered drug products in the market. The FDA said that drug products Jingzhi Niuhuang Jiedu Pian Tablet, Sanqi Huazhi Pills, Sumalin Sugar-Coated Tablets 100's, DK Gastrointestinal Regulating Pills (Intestinal Medicine), Anti-Tumour Anti Cancer Pill 0.25g 100 slices, and Anxin Tablets (Anti-Hypertensive Compound Tablets) 100's were found unregistered with the agency. Jingzhi Niuhuang Jiedu Pian Tablet, Sanqi Huazhi Pills, Sumalin Sugar-Coated Tablets 100's, DK Gastrointestinal Regulating Pills (Intestinal Medicine), Anti-Tumour Anti Cancer Pill 0.25g 100 slices, and Anxin Tablets (Anti-Hypertensive Compound Tablets) (FDA / MANILA BULLETIN) "Since these unregistered drug products have not gone through evaluation and testing process of the FDA, the agency cannot guarantee their efficacy, quality, and safety," said the agency in its advisory no. 2019-148. "These violative products may pose potential danger or injury if administered. In light of the above, the public is advised not to purchase the aforementioned violative products," it added. The agency has called on concerned establishment not to distribute the said drug products "until these have already been covered by the appropriate authorization." The FDA also requested local government units and law enforcement units to ensure that the said products are not sold or made available in their areas of jurisdiction. The public was also encouraged to visit the FDA website to check if a drug product is registered with the agency.